HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.

Abstract
Previous NMR studies demonstrated that lonidamine (LND) selectively diminishes the intracellular pH (pHi) of DB-1 melanoma and mouse xenografts of a variety of other prevalent human cancers while decreasing their bioenergetic status (tumor βNTP/Pi ratio) and enhancing the activities of melphalan and doxorubicin in these cancer models. Since melphalan and doxorubicin are highly toxic agents, we have examined three other nitrogen (N)-mustards, chlorambucil, cyclophosphamide and bendamustine, to determine if they exhibit similar potentiation by LND. As single agents LND, melphalan and these N-mustards exhibited the following activities in DB-1 melanoma xenografts; LND: 100% tumor surviving fraction (SF); chlorambucil: 100% SF; cyclophosphamide: 100% SF; bendamustine: 79% SF; melphalan: 41% SF. When combined with LND administered 40 min prior to administration of the N-mustard (to maximize intracellular acidification) the following responses were obtained; chlorambucil: 62% SF; cyclophosphamide: 42% SF; bendamustine: 36% SF; melphalan: 10% SF. The effect of LND on the activities of these N-mustards is generally attributed to acid stabilization of the aziridinium active intermediate, acid inhibition of glutathione-S-transferase, which acts as a scavenger of aziridinium, and acid inhibition of DNA repair by O6-alkyltransferase. Depletion of ATP by LND may also decrease multidrug resistance and increase tumor response. At similar maximum tolerated doses, our data indicate that melphalan is the most effective N-mustard in combination with LND when treating DB-1 melanoma in mice, but the choice of N-mustard for coadministration with LND will also depend on the relative toxicities of these agents, and remains to be determined.
AuthorsKavindra Nath, David S Nelson, Mary E Putt, Dennis B Leeper, Bradley Garman, Katherine L Nathanson, Jerry D Glickson
JournalPloS one (PLoS One) Vol. 11 Issue 6 Pg. e0157125 ( 2016) ISSN: 1932-6203 [Electronic] United States
PMID27285585 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Alkylating Agents
  • Indazoles
  • Chlorambucil
  • Mechlorethamine
  • Doxorubicin
  • Cyclophosphamide
  • Melphalan
  • lonidamine
Topics
  • Alkylating Agents (pharmacology)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Chlorambucil (pharmacology)
  • Cyclophosphamide (pharmacology)
  • Doxorubicin (pharmacology)
  • Drug Synergism
  • Humans
  • Indazoles (pharmacology)
  • Male
  • Mechlorethamine (pharmacology)
  • Melanoma (drug therapy, pathology)
  • Melphalan (pharmacology)
  • Mice
  • Mice, Nude
  • Mice, SCID
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: